Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
At launch of updated pediatric gastroenterology textbook, Union Minister says technology must strengthen not substitute core medical learning
The results were consistent across both the 10 mg and 40 mg treatment arms
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Capital infusion to accelerate Earendil’s R&D platform
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Subscribe To Our Newsletter & Stay Updated
